Molecular Physiology — MCQs

Q: A genetic study identifies a family with multiple members having early-onset colorectal cancer. DNA mismatch repair gene testing reveals a mutation in MLH1 gene. Which molecular phenomenon would be most prominently observed in tumor cells from these patients?

Microsatellite instability (MSI). ***Microsatellite instability (MSI)*** - Mutations in **MLH1** lead to defective **DNA mismatch repair (MMR)**, which is the hallmark of **Lynch syndrome** (HNPCC). - Failure to repair errors in repetitive DNA sequences results in **microsatellite instability**, characterized by the expansion or contraction of short tandem repeats in tumor cells. *Chromosomal translocations* - These are typical of **hematologic malignancies** (e.g., Philadelphia chromosome in CML) or certain sarcomas, rather than MMR defects. - Lynch syndrome tumors usually exhibit **diploidy** and stable karyotypes compared to tumors following the **chromosomal instability (CIN)** pathway. *Telomere shortening* - This is a feature of **cellular senescence** and aging, where repeating sequences at the end of chromosomes are lost over time. - Cancer cells generally find ways to **maintain telomere length** (via telomerase) rather than experiencing shortening, which would limit their proliferative capacity. *DNA methylation* - While **hypermethylation** of the MLH1 promoter can cause sporadic MSI, this case specifies a **germline mutation** in a genetic study context. - Methylation is an **epigenetic modification** that affects gene expression but is not the primary molecular consequence arising directly from the loss of DNA repair enzyme function.

Q: A 45-year-old woman with breast cancer is being treated with trastuzumab (Herceptin). Laboratory analysis of her tumor cells shows 100-fold amplification of a specific gene. Analysis of the signal transduction pathway reveals constitutive activation of PI3K/AKT pathway. Which receptor is most likely overexpressed?

Human epidermal growth factor receptor 2 (HER2). ***Human epidermal growth factor receptor 2 (HER2)*** - **Trastuzumab** is a monoclonal antibody specifically designed to target the **HER2/neu (ERBB2)** receptor, which is overexpressed in approximately 20-30% of breast cancers. - **HER2** is a receptor tyrosine kinase that, when amplified, leads to constitutive activation of the **PI3K/AKT** and **MAPK** pathways, driving uncontrolled cell proliferation. *Vascular endothelial growth factor receptor (VEGFR)* - **VEGFR** is primarily involved in **angiogenesis** (the formation of new blood vessels) and is the target of drugs like **bevacizumab**, not trastuzumab. - While important in many cancers, its signaling pathway is not the primary target in the standard clinical use of trastuzumab for breast cancer. *Progesterone receptor (PR)* - **PR** is a **nuclear receptor** that functions as a transcription factor, not a cell surface receptor tyrosine kinase that activates the **PI3K/AKT** pathway directly. - Overexpression of PR is managed with **hormonal therapies** (like aromatase inhibitors), but it is not the target of the antibody **trastuzumab**. *Estrogen receptor (ER)* - Similar to the progesterone receptor, the **ER** is an intracellular receptor used to guide treatment with drugs like **Tamoxifen**. - Genes for ER are not typically subject to the **100-fold amplification** described, as ER status is usually determined by ligand-dependent signaling rather than massive gene duplication.

Q: A researcher is studying a cell line that shows resistance to apoptosis despite DNA damage. Analysis reveals overexpression of a protein that normally prevents p53 from inducing cell cycle arrest. Which protein is most likely overexpressed?

MDM2. ***MDM2*** - **MDM2** functions as an **E3 ubiquitin ligase** that directly binds to **p53**, promoting its degradation and inhibiting its transcriptional activity. - Overexpression leads to the loss of **p53-mediated cell cycle arrest** (via p21) and apoptosis, allowing cells with **DNA damage** to survive and proliferate. *Caspase-3* - **Caspase-3** is an **executioner caspase** that plays a central role in the final stages of the apoptotic cascade, not the regulation of p53. - Overexpression would typically **promote apoptosis** rather than providing resistance to it after DNA damage. *Cytochrome C* - **Cytochrome C** is released from the **mitochondria** into the cytosol to activate the **apoptosome** during the intrinsic pathway of apoptosis. - Its release occurs **downstream** of p53 activation and is not a protein that inhibits p53-induced cell cycle arrest. *Bcl-2* - **Bcl-2** is an **anti-apoptotic** protein that prevents the release of Cytochrome C, but it does not directly regulate p53-mediated **cell cycle arrest**. - While its overexpression prevents apoptosis, the specific mechanism of inhibiting **p53's ability to induce arrest** points towards MDM2.

Q: Which enzyme is responsible for unwinding the DNA double helix during replication?

Helicase. ***Helicase*** - **Helicase** is the specific enzyme responsible for **unwinding** the DNA double helix by breaking **hydrogen bonds** between complementary nitrogenous bases. - This action creates the **replication fork**, providing the single-stranded templates necessary for the replication process to proceed. *DNA polymerase* - Its primary role is the **synthesis** of new DNA strands by adding **deoxyribonucleotides** to a pre-existing primer. - It possesses **proofreading** capabilities but cannot physically separate the two parent strands of the DNA molecule. *Topoisomerase* - This enzyme functions to relieve **torsional strain** and prevent **supercoiling** of the DNA ahead of the replication fork. - It works by creating transient **single or double-stranded breaks** in the DNA backbone rather than unwinding the helix for template access. *DNA ligase* - Its main function is to join **Okazaki fragments** on the lagging strand by catalyzing the formation of **phosphodiester bonds**. - It acts as a molecular glue during the final stages of replication and **DNA repair**, not during the initial unwinding phase.

Q: Which type of RNA carries amino acids to the ribosome during protein synthesis?

Transfer RNA (tRNA). ***Transfer RNA (tRNA)*** - **tRNA** acts as an adapter molecule that matches specific **amino acids** to their corresponding **codons** on the mRNA template. - It contains an **anticodon loop** that base-pairs with mRNA and a 3' end that covalently binds the amino acid via **aminoacyl-tRNA synthetase**. *Ribosomal RNA (rRNA)* - **rRNA** is a structural and catalytic component of the **ribosome**, providing the scaffold for protein assembly. - It facilitates the formation of **peptide bonds** through its **peptidyl transferase** activity but does not transport amino acids. *Small nuclear RNA (snRNA)* - **snRNA** is primarily involved in the **splicing** of pre-messenger RNA within the nucleus. - It combines with proteins to form **snRNPs** (spliceosomes) and is not directly involved in the translation process at the ribosome. *Messenger RNA (mRNA)* - **mRNA** serves as the genetic blueprint that carries the **coding sequence** from DNA to the ribosome for translation. - It provides the **template** of codons that dictates the specific sequence of amino acids rather than transporting them.

A research team is developing a gene therapy approach using CRISPR-Cas9 to correct a point mutation causing sickle cell disease. They must decide between two strategies: (A) correcting the mutation in hematopoietic stem cells ex vivo, or (B) in vivo correction in bone marrow. Considering molecular physiology principles, what is the most significant advantage of strategy A over strategy B?

A novel drug is designed to treat a genetic disorder caused by a nonsense mutation in the dystrophin gene. The drug works by allowing the ribosome to skip over the premature stop codon and continue translation. Evaluation of this therapeutic strategy reveals partial restoration of dystrophin protein with 60% of normal length but sufficient function. What is the most critical molecular consideration in determining if this approach will be clinically beneficial?

A genetic study identifies a family with multiple members having early-onset colorectal cancer. DNA mismatch repair gene testing reveals a mutation in MLH1 gene. Which molecular phenomenon would be most prominently observed in tumor cells from these patients?

A 45-year-old woman with breast cancer is being treated with trastuzumab (Herceptin). Laboratory analysis of her tumor cells shows 100-fold amplification of a specific gene. Analysis of the signal transduction pathway reveals constitutive activation of PI3K/AKT pathway. Which receptor is most likely overexpressed?

A researcher is studying a cell line that shows resistance to apoptosis despite DNA damage. Analysis reveals overexpression of a protein that normally prevents p53 from inducing cell cycle arrest. Which protein is most likely overexpressed?

A 6-month-old infant presents with severe anemia, jaundice, and hepatosplenomegaly. Hemoglobin electrophoresis shows predominantly HbF (fetal hemoglobin) with absent HbA. Which molecular defect best explains this clinical picture?

How does alternative splicing contribute to protein diversity in humans despite having approximately 20,000 genes?

Why does DNA replication occur in a 5' to 3' direction only?

Which enzyme is responsible for unwinding the DNA double helix during replication?

Q10

Which type of RNA carries amino acids to the ribosome during protein synthesis?

Molecular Physiology Indian Medical PG Practice Questions and MCQs

Question 1: A research team is developing a gene therapy approach using CRISPR-Cas9 to correct a point mutation causing sickle cell disease. They must decide between two strategies: (A) correcting the mutation in hematopoietic stem cells ex vivo, or (B) in vivo correction in bone marrow. Considering molecular physiology principles, what is the most significant advantage of strategy A over strategy B?

A. Strategy A allows for screening and selection of successfully edited cells before transplantation, minimizing off-target effects (Correct Answer)
B. Strategy A requires lower doses of viral vectors
C. Strategy A produces faster clinical improvement
D. Strategy A is less expensive to implement

Explanation: ***Strategy A allows for screening and selection of successfully edited cells before transplantation, minimizing off-target effects*** - **Ex vivo** correction allows scientists to perform **quality control** by screening the patient's cells for the desired **on-target** modification and ensuring no harmful **off-target** mutations exist. - This selection process ensures that only **genetically verified** hematopoietic stem cells are re-infused, providing a significant safety and efficacy profile compared to blind **in vivo** delivery. *Strategy A requires lower doses of viral vectors* - While the total volume might be smaller, the primary advantage is the **precision** and **safety** of editing, not merely the quantity of the vector used. - **In vivo** methods actually face greater challenges with **vector distribution** and immune clearance, but this is less critical than the ability to screen cells. *Strategy A produces faster clinical improvement* - The **ex vivo** process is time-consuming, involving **cell harvesting**, laboratory editing, and **myeloablative conditioning** before re-infusion. - Clinical improvement depends on the **engraftment** of edited cells and the turnover of red blood cells, which is not necessarily faster than **in vivo** methods. *Strategy A is less expensive to implement* - **Ex vivo** gene therapy is highly expensive due to the need for **specialized laboratory facilities**, intensive cell culture protocols, and prolonged patient **hospitalization**. - **In vivo** strategies are conceptually cheaper and easier to scale, but currently lack the **safety oversight** provided by laboratory screening.

Question 2: A novel drug is designed to treat a genetic disorder caused by a nonsense mutation in the dystrophin gene. The drug works by allowing the ribosome to skip over the premature stop codon and continue translation. Evaluation of this therapeutic strategy reveals partial restoration of dystrophin protein with 60% of normal length but sufficient function. What is the most critical molecular consideration in determining if this approach will be clinically beneficial?

A. Whether the drug prevents degradation of dystrophin mRNA
B. Whether the drug enhances ribosomal binding to the start codon
C. Whether the drug increases transcription of the dystrophin gene
D. Whether the truncated protein retains the actin-binding domain and maintains membrane stability (Correct Answer)

Explanation: ***Whether the truncated protein retains the actin-binding domain and maintains membrane stability*** - For a truncated **dystrophin** protein to be clinically effective, it must preserve the functional linkage between the **actin cytoskeleton** and the **extracellular matrix**. - This is the fundamental mechanism behind converting a severe **Duchenne** phenotype into a milder **Becker** muscular dystrophy phenotype through **read-through** or exon-skipping therapies. *Whether the drug prevents degradation of dystrophin mRNA* - While **nonsense-mediated decay (NMD)** can reduce mRNA levels in nonsense mutations, preventing degradation is useless if the resulting translation still produces a non-functional protein. - The primary goal of read-through therapy is the quality and **functional domains** of the protein produced, rather than just the quantity of mRNA present. *Whether the drug enhances ribosomal binding to the start codon* - Enhancing **ribosomal binding** to the **start codon** (AUG) might increase the initiation of translation but does not address the premature stop codon issue. - Clinical benefit depends on the ribosome's ability to bypass the **premature termination codon (PTC)**, not the efficiency of initial binding. *Whether the drug increases transcription of the dystrophin gene* - Increasing **transcription** would only result in more mutated mRNA transcripts, which would still terminate at the **premature stop codon**. - Without a mechanism to ensure a functional protein product, simply increasing **gene expression** does not mitigate the mechanical instability of the muscle cell membrane.

Question 3: A genetic study identifies a family with multiple members having early-onset colorectal cancer. DNA mismatch repair gene testing reveals a mutation in MLH1 gene. Which molecular phenomenon would be most prominently observed in tumor cells from these patients?

A. Chromosomal translocations
B. Telomere shortening
C. DNA methylation
D. Microsatellite instability (MSI) (Correct Answer)

Explanation: ***Microsatellite instability (MSI)*** - Mutations in **MLH1** lead to defective **DNA mismatch repair (MMR)**, which is the hallmark of **Lynch syndrome** (HNPCC). - Failure to repair errors in repetitive DNA sequences results in **microsatellite instability**, characterized by the expansion or contraction of short tandem repeats in tumor cells. *Chromosomal translocations* - These are typical of **hematologic malignancies** (e.g., Philadelphia chromosome in CML) or certain sarcomas, rather than MMR defects. - Lynch syndrome tumors usually exhibit **diploidy** and stable karyotypes compared to tumors following the **chromosomal instability (CIN)** pathway. *Telomere shortening* - This is a feature of **cellular senescence** and aging, where repeating sequences at the end of chromosomes are lost over time. - Cancer cells generally find ways to **maintain telomere length** (via telomerase) rather than experiencing shortening, which would limit their proliferative capacity. *DNA methylation* - While **hypermethylation** of the MLH1 promoter can cause sporadic MSI, this case specifies a **germline mutation** in a genetic study context. - Methylation is an **epigenetic modification** that affects gene expression but is not the primary molecular consequence arising directly from the loss of DNA repair enzyme function.

Question 4: A 45-year-old woman with breast cancer is being treated with trastuzumab (Herceptin). Laboratory analysis of her tumor cells shows 100-fold amplification of a specific gene. Analysis of the signal transduction pathway reveals constitutive activation of PI3K/AKT pathway. Which receptor is most likely overexpressed?

A. Human epidermal growth factor receptor 2 (HER2) (Correct Answer)
B. Vascular endothelial growth factor receptor (VEGFR)
C. Progesterone receptor (PR)
D. Estrogen receptor (ER)

Explanation: ***Human epidermal growth factor receptor 2 (HER2)*** - **Trastuzumab** is a monoclonal antibody specifically designed to target the **HER2/neu (ERBB2)** receptor, which is overexpressed in approximately 20-30% of breast cancers. - **HER2** is a receptor tyrosine kinase that, when amplified, leads to constitutive activation of the **PI3K/AKT** and **MAPK** pathways, driving uncontrolled cell proliferation. *Vascular endothelial growth factor receptor (VEGFR)* - **VEGFR** is primarily involved in **angiogenesis** (the formation of new blood vessels) and is the target of drugs like **bevacizumab**, not trastuzumab. - While important in many cancers, its signaling pathway is not the primary target in the standard clinical use of trastuzumab for breast cancer. *Progesterone receptor (PR)* - **PR** is a **nuclear receptor** that functions as a transcription factor, not a cell surface receptor tyrosine kinase that activates the **PI3K/AKT** pathway directly. - Overexpression of PR is managed with **hormonal therapies** (like aromatase inhibitors), but it is not the target of the antibody **trastuzumab**. *Estrogen receptor (ER)* - Similar to the progesterone receptor, the **ER** is an intracellular receptor used to guide treatment with drugs like **Tamoxifen**. - Genes for ER are not typically subject to the **100-fold amplification** described, as ER status is usually determined by ligand-dependent signaling rather than massive gene duplication.

Question 5: A researcher is studying a cell line that shows resistance to apoptosis despite DNA damage. Analysis reveals overexpression of a protein that normally prevents p53 from inducing cell cycle arrest. Which protein is most likely overexpressed?

A. MDM2 (Correct Answer)
B. Caspase-3
C. Cytochrome C
D. Bcl-2

Explanation: ***MDM2*** - **MDM2** functions as an **E3 ubiquitin ligase** that directly binds to **p53**, promoting its degradation and inhibiting its transcriptional activity. - Overexpression leads to the loss of **p53-mediated cell cycle arrest** (via p21) and apoptosis, allowing cells with **DNA damage** to survive and proliferate. *Caspase-3* - **Caspase-3** is an **executioner caspase** that plays a central role in the final stages of the apoptotic cascade, not the regulation of p53. - Overexpression would typically **promote apoptosis** rather than providing resistance to it after DNA damage. *Cytochrome C* - **Cytochrome C** is released from the **mitochondria** into the cytosol to activate the **apoptosome** during the intrinsic pathway of apoptosis. - Its release occurs **downstream** of p53 activation and is not a protein that inhibits p53-induced cell cycle arrest. *Bcl-2* - **Bcl-2** is an **anti-apoptotic** protein that prevents the release of Cytochrome C, but it does not directly regulate p53-mediated **cell cycle arrest**. - While its overexpression prevents apoptosis, the specific mechanism of inhibiting **p53's ability to induce arrest** points towards MDM2.

Question 6: A 6-month-old infant presents with severe anemia, jaundice, and hepatosplenomegaly. Hemoglobin electrophoresis shows predominantly HbF (fetal hemoglobin) with absent HbA. Which molecular defect best explains this clinical picture?

A. Deletion in alpha-globin gene causing alpha-thalassemia
B. Point mutation in beta-globin gene causing sickle cell disease
C. Deletion or mutation in beta-globin gene causing beta-thalassemia major (Correct Answer)
D. Mutation in gamma-globin gene

Explanation: ***Deletion or mutation in beta-globin gene causing beta-thalassemia major*** - This condition, also known as **Cooley's anemia**, results in a total or near-total absence of **beta-globin chain** production, leading to an **absence of HbA** (α2β2). - Symptoms manifest at approximately 6 months of age as **HbF** (α2γ2) production normally declines, resulting in **severe microcytic anemia**, **jaundice**, and compensatory **extramedullary hematopoiesis** (hepatosplenomegaly). *Deletion in alpha-globin gene causing alpha-thalassemia* - **Alpha-thalassemia** typically involves deletions of the alpha-globin genes; if severe (Hydrops Fetalis), it presents at birth with **Hb Barts** (γ4), not HbF. - Since alpha chains are required for HbF (α2γ2), a total absence of alpha-globin would prevent the formation of **fetal hemoglobin** entirely. *Point mutation in beta-globin gene causing sickle cell disease* - **Sickle cell disease** is caused by a specific **missense mutation** (glutamate to valine) and would show **HbS** on electrophoresis rather than a predominance of HbF with absent HbA. - While patients with sickle cell may have elevated HbF, it is the presence of **HbS** and characteristic **vaso-occlusive crises** that differentiate it from beta-thalassemia major. *Mutation in gamma-globin gene* - Mutations in the **gamma-globin gene** would affect fetal development and the production of **HbF**, which is the predominant hemoglobin shown in this infant. - A defect here would not cause the **absence of HbA**, as HbA production is dependent on the beta-globin gene, which occurs later in development.

Question 7: How does alternative splicing contribute to protein diversity in humans despite having approximately 20,000 genes?

A. By modifying amino acids after translation
B. By changing the sequence of codons in the mRNA
C. By producing different tRNA molecules
D. By allowing different combinations of exons to be included in mature mRNA (Correct Answer)

Explanation: ***By allowing different combinations of exons to be included in mature mRNA*** - **Alternative splicing** allows a single gene to encode multiple protein isoforms by selectively including or excluding specific **exons** during pre-mRNA processing. - This mechanism is a key driver of **proteomic diversity**, enabling the human genome to produce significantly more proteins than the number of available genes. *By modifying amino acids after translation* - This refers to **post-translational modifications** (e.g., phosphorylation, glycosylation), which occur after the protein has already been synthesized. - While it increases functional diversity, it does not involve the **mRNA splicing** process or the primary arrangement of exons. *By changing the sequence of codons in the mRNA* - Changing the sequence of individual codons is typically associated with **RNA editing** or mutations, rather than standard alternative splicing. - **Alternative splicing** rearranges existing coding blocks (exons) rather than altering the specific nucleotide sequence within a single codon. *By producing different tRNA molecules* - **tRNA molecules** are adapters used during translation to match amino acids to codons; they do not determine the **exon structure** of mRNA. - Variation in tRNA does not explain how a specific gene sequence yields multiple unique **protein isoforms**.

Question 8: Why does DNA replication occur in a 5' to 3' direction only?

A. Because DNA polymerase can only add nucleotides to the 3'-OH group (Correct Answer)
B. Because primase can only synthesize primers in that direction
C. Because the template strand is read in 3' to 5' direction only
D. Because helicase unwinds DNA in only one direction

Explanation: ***Because DNA polymerase can only add nucleotides to the 3'-OH group*** - **DNA polymerase** requires a free **3'-hydroxyl (OH) group** to catalyze the formation of a **phosphodiester bond** with the incoming 5'-phosphate of a dNTP. - This biochemical constraint ensures that the new DNA strand is synthesized exclusively in the **5' to 3' direction**, providing energy for the reaction via the cleavage of pyrophosphate. *Because primase can only synthesize primers in that direction* - While **primase** does synthesize RNA primers in a 5' to 3' direction, it is not the primary reason for the overall directional constraint of **DNA elongation**. - Primase merely provides the initial **3'-OH scaffold** that DNA polymerase requires to begin its work. *Because the template strand is read in 3' to 5' direction only* - The fact that the **template strand** is read in the 3' to 5' direction is a consequence of the **antiparallel** nature of DNA, not the underlying cause for the limitation. - The fundamental restriction lies in the **enzymatic specificity** of the polymerase rather than the orientation of the template itself. *Because helicase unwinds DNA in only one direction* - **Helicase** functions by breaking hydrogen bonds at the **replication fork**, and its movement is independent of the chemical requirements for adding new nucleotides. - Even though helicase moves in one direction, DNA synthesis must still occur in a **5' to 3' fashion** on both the leading and lagging strands.

Question 9: Which enzyme is responsible for unwinding the DNA double helix during replication?

A. DNA polymerase
B. Helicase (Correct Answer)
C. Topoisomerase
D. DNA ligase

Explanation: ***Helicase*** - **Helicase** is the specific enzyme responsible for **unwinding** the DNA double helix by breaking **hydrogen bonds** between complementary nitrogenous bases. - This action creates the **replication fork**, providing the single-stranded templates necessary for the replication process to proceed. *DNA polymerase* - Its primary role is the **synthesis** of new DNA strands by adding **deoxyribonucleotides** to a pre-existing primer. - It possesses **proofreading** capabilities but cannot physically separate the two parent strands of the DNA molecule. *Topoisomerase* - This enzyme functions to relieve **torsional strain** and prevent **supercoiling** of the DNA ahead of the replication fork. - It works by creating transient **single or double-stranded breaks** in the DNA backbone rather than unwinding the helix for template access. *DNA ligase* - Its main function is to join **Okazaki fragments** on the lagging strand by catalyzing the formation of **phosphodiester bonds**. - It acts as a molecular glue during the final stages of replication and **DNA repair**, not during the initial unwinding phase.

Question 10: Which type of RNA carries amino acids to the ribosome during protein synthesis?

A. Ribosomal RNA (rRNA)
B. Small nuclear RNA (snRNA)
C. Transfer RNA (tRNA) (Correct Answer)
D. Messenger RNA (mRNA)

Explanation: ***Transfer RNA (tRNA)*** - **tRNA** acts as an adapter molecule that matches specific **amino acids** to their corresponding **codons** on the mRNA template. - It contains an **anticodon loop** that base-pairs with mRNA and a 3' end that covalently binds the amino acid via **aminoacyl-tRNA synthetase**. *Ribosomal RNA (rRNA)* - **rRNA** is a structural and catalytic component of the **ribosome**, providing the scaffold for protein assembly. - It facilitates the formation of **peptide bonds** through its **peptidyl transferase** activity but does not transport amino acids. *Small nuclear RNA (snRNA)* - **snRNA** is primarily involved in the **splicing** of pre-messenger RNA within the nucleus. - It combines with proteins to form **snRNPs** (spliceosomes) and is not directly involved in the translation process at the ribosome. *Messenger RNA (mRNA)* - **mRNA** serves as the genetic blueprint that carries the **coding sequence** from DNA to the ribosome for translation. - It provides the **template** of codons that dictates the specific sequence of amino acids rather than transporting them.

Question 11: Which receptor binds to Brain-Derived Neurotrophic Factor (BDNF)?

A. TrK-A
B. TrK-B (Correct Answer)
C. TrK-C
D. None of the above

Explanation: ### Explanation **Neurotrophins** are a family of proteins essential for the survival, development, and function of neurons. They exert their effects by binding to specific high-affinity transmembrane tyrosine kinase receptors known as **TrK (Tropomyosin receptor kinase)** receptors. **Why TrK-B is the Correct Answer:** Each neurotrophin has a specific affinity for a particular TrK receptor. **Brain-Derived Neurotrophic Factor (BDNF)** and **Neurotrophin-4/5 (NT-4/5)** specifically bind to **TrK-B**. Upon binding, BDNF triggers dimerization and autophosphorylation of the receptor, activating downstream signaling pathways (like MAPK and PI3K) that promote neuronal plasticity, long-term potentiation (LTP), and cell survival. **Analysis of Incorrect Options:** * **Option A (TrK-A):** This is the primary receptor for **Nerve Growth Factor (NGF)**. It is crucial for the survival of sympathetic and sensory neurons. * **Option C (TrK-C):** This receptor specifically binds to **Neurotrophin-3 (NT-3)**. NT-3 is unique because it can also bind to TrK-A and TrK-B with lower affinity, but TrK-C is its primary target. **High-Yield NEET-PG Pearls:** 1. **p75NTR Receptor:** All neurotrophins (NGF, BDNF, NT-3, NT-4/5) bind with low affinity to the **p75 neurotrophin receptor**, which often mediates apoptosis (cell death) rather than survival. 2. **BDNF & Memory:** BDNF is highly expressed in the **hippocampus** and is a key molecular mediator of synaptic plasticity and memory formation. 3. **Clinical Correlation:** Reduced levels of BDNF are implicated in the pathogenesis of **Depression** and **Alzheimer’s disease**. Antidepressants often work by increasing BDNF expression. 4. **Mnemonic:** * **A**-NGF (A comes first, like NGF discovery) * **B**-BDNF (B for B) * **C**-NT-3 (C is the 3rd letter)

Question 12: Which of the following is not a channelopathy?

A. Cystic fibrosis
B. Liddle's syndrome
C. Tay-sach's disease (Correct Answer)
D. Hypokalemic periodic paralysis

Explanation: **Explanation:** **Channelopathies** are a group of disorders caused by mutations in genes encoding ion channel proteins or their regulatory subunits, leading to dysfunctional ion transport across cell membranes. **Why Tay-Sachs Disease is the Correct Answer:** Tay-Sachs disease is **not** a channelopathy; it is a **Lysosomal Storage Disorder**. It is caused by a deficiency of the enzyme **Hexosaminidase A**, leading to the toxic accumulation of GM2 gangliosides in neurons. Clinically, it presents with neurodegeneration, developmental delay, and a characteristic **cherry-red spot** on the macula. **Analysis of Incorrect Options:** * **Cystic Fibrosis:** This is a classic channelopathy caused by mutations in the **CFTR gene**, which encodes a cAMP-regulated **Chloride channel**. Dysfunction leads to thick, viscid secretions in the lungs and pancreas. * **Liddle’s Syndrome:** A genetic form of hypertension caused by a "gain-of-function" mutation in the **ENaC (Epithelial Sodium Channel)** in the collecting ducts of the kidney, leading to excessive sodium reabsorption. * **Hypokalemic Periodic Paralysis:** A skeletal muscle channelopathy most commonly involving the **voltage-gated Calcium channel (Cav1.1)** or Sodium channel (Nav1.4), resulting in episodes of muscle weakness triggered by low serum potassium. **High-Yield Clinical Pearls for NEET-PG:** * **Common Channelopathies to Remember:** Lambert-Eaton Syndrome (Ca²⁺ channel), Myasthenia Gravis (ACh-gated Na⁺ channel), and Long QT Syndrome (K⁺/Na⁺ channels). * **Bartter’s and Gitelman’s Syndromes** are also important renal channelopathies involving salt transporters. * **Tay-Sachs Mnemonic:** "A **Gang** of **Six** (**Hex**osaminidase) **Small** (**Tay**-Sachs) **Cherries** (Cherry-red spot)."

Question 13: Which of the following conditions CAN BE transmitted as a recessive, sex-linked trait? I. Retinitis pigmentosa II. Colour blindness III. Cystic fibrosis IV. Duchenne muscular dystrophy Select the correct answer using the code given below :

A. II, III and IV
B. I, II and IV (Correct Answer)
C. I, II and III
D. I, III and IV

Explanation: ***I, II and IV*** - All three conditions listed—**Retinitis Pigmentosa**, **Colour Blindness**, and **Duchenne Muscular Dystrophy**—can be inherited as recessive, **sex-linked traits**. - **Sex-linked inheritance** primarily refers to genes located on the **X chromosome**; males are more frequently affected because they have only one X chromosome. *II, III and IV* - This option incorrectly includes **Cystic Fibrosis**, which is an **autosomal recessive disorder**, not a sex-linked trait. - While **Colour Blindness** and **Duchenne Muscular Dystrophy** are sex-linked, their grouping with an autosomal condition makes this option incorrect. *I, II and III* - This option also incorrectly includes **Cystic Fibrosis** as a sex-linked trait. - **Retinitis Pigmentosa** and **Colour Blindness** can be sex-linked, but the inclusion of **Cystic Fibrosis** renders the entire option incorrect. *I, III and IV* - This option incorrectly includes **Cystic Fibrosis**; it is an **autosomal recessive condition**, not sex-linked. - Although **Retinitis Pigmentosa** and **Duchenne Muscular Dystrophy** are correctly identified as conditions that can be sex-linked, the incorrect inclusion of **Cystic Fibrosis** makes this option wrong.

Question 14: Which one of the following correctly denotes the inheritance pattern of cystic fibrosis?

A. X-linked Dominant
B. Autosomal Recessive (Correct Answer)
C. Autosomal Dominant
D. X-linked Recessive

Explanation: ***Autosomal Recessive*** - Cystic fibrosis is an **autosomal recessive** disorder, meaning an individual must inherit **two copies** of the defective gene (one from each parent) to develop the condition. - Parents who are **carriers** (having one normal and one defective gene) typically do not show symptoms but can pass the gene to their children. *X-linked Dominant* - In **X-linked dominant** inheritance, a single copy of a mutated gene on the X chromosome is sufficient to cause the disorder. - This pattern would show common inheritance in females and often more severe phenotypes in males, which is not characteristic of cystic fibrosis. *Autosomal Dominant* - **Autosomal dominant** disorders require only **one copy** of a mutated gene on a non-sex chromosome for the disease to manifest. - If cystic fibrosis were autosomal dominant, affected individuals would typically have an affected parent, and the disease would be much more prevalent than observed. *X-linked Recessive* - **X-linked recessive** disorders primarily affect males, as they have only one X chromosome. Females are typically carriers and less severely affected. - Cystic fibrosis affects males and females nearly equally, which rules out an X-linked recessive inheritance pattern.

Question 15: Otosclerosis is inherited in which manner?

A. Autosomal dominant (Correct Answer)
B. Autosomal recessive
C. X-linked dominant
D. X-linked recessive

Explanation: ***Autosomal dominant*** - **Otospongiosis**, also known as **otosclerosis**, is most frequently inherited in an autosomal dominant pattern with **incomplete penetrance**. - This means that a single copy of the altered gene is sufficient to cause the condition, but not everyone who inherits the gene will develop symptoms. *Autosomal recessive* - **Autosomal recessive** inheritance requires two copies of the altered gene (one from each parent) for the condition to manifest. - This pattern is less common for otospongiosis and not considered the primary mode of inheritance. *X-linked dominant* - **X-linked dominant** inheritance affects both males and females, but typically males are more severely affected than females. - While otospongiosis shows some sex differences in presentation, its inheritance pattern is not primarily linked to the X chromosome in a dominant fashion. *X-linked recessive* - **X-linked recessive** inheritance primarily affects males since they only have one X chromosome, and females are typically carriers. - This pattern is not characteristic of otospongiosis, as evidence shows a significant transmission to both sexes from affected individuals.

Question 16: The gene that regulates normal morphogenesis during development is?

A. FMR-1 gene
B. P-16
C. Homeobox gene (Correct Answer)
D. PTEN

Explanation: ***Homeobox gene*** - **Homeobox genes** (Hox genes) are a large family of genes that play a critical role in regulating the **patterning of the body axis** and the **development of organs** and appendages during embryonic development. - They encode **transcription factors** that control the expression of other genes involved in morphogenesis. *FMR-1 gene* - The **FMR-1 gene** (fragile X mental retardation 1 gene) is associated with **Fragile X syndrome**, a genetic condition causing intellectual disability and developmental problems. - Its primary role is in **brain development** and synaptic function, not general normal morphogenesis. *P-16* - **P16 (CDKN2A)** is a **tumor suppressor gene** involved in regulating the cell cycle by inhibiting cyclin-dependent kinases. - Its main function is in preventing uncontrolled cell growth and proliferation, not directly in orchestrating embryonic morphogenesis. *PTEN* - **PTEN** is another prominent **tumor suppressor gene** that plays a crucial role in cell growth, survival, and proliferation. - Mutations in PTEN are linked to various cancers and developmental disorders such as **Cowden syndrome**, but its primary function is not in regulating the broad aspects of normal embryonic morphogenesis.

Practice by Chapter

Protein Structure and Function

Practice Questions

Nucleic Acid Structure and Function

Practice Questions

Gene Expression and Regulation

Practice Questions

Molecular Basis of Enzyme Function

Practice Questions

Post-Translational Modifications

Practice Questions

Receptor-Ligand Interactions

Practice Questions

Signal Transduction Pathways

Practice Questions

Molecular Basis of Excitability

Practice Questions

Molecular Motors and Cytoskeleton

Practice Questions

Molecular Techniques in Physiology

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free